At least 2 percent of people over age 40 and 5 percent of people over 70 have mutations linked to leukemia and lymphoma in their blood cells, according to new research led by Li Ding, PhD, at the School of Medicine.
Studying the most common type of lung cancer, researchers from The Cancer Genome Atlas have uncovered new mutations in a cell-signaling pathway that plays a role in forming tumors. The new knowledge may expand treatments for patients because drugs targeting some of these genetic changes already are available or are in clinical trials.
A consortium of researchers led by the School of Medicine has identified virtually all of the major mutations that drive acute myeloid leukemia (AML), a fast-growing blood cancer in adults that often is difficult to treat. The dark lines in the image pictured show all of the major mutations for AML that occurred in one patient with the disease.
The most in-depth look yet at endometrial cancer shows that adding genomics-based testing to the standard diagnostic workup could change the recommended course of treatment for some women. The new research is published in the journal Nature. Pictured are endometrial cancer cells under a microscope.
The most comprehensive analysis yet of breast tumors shows that one of the most deadly subtypes shares many genetic features with similarly lethal ovarian tumors.
A nationwide consortium of scientists has reported the first comprehensive genetic analysis of squamous cell carcinoma of the lung, a common type of lung cancer responsible for about 400,000 deaths each year. According to Ramaswamy Govindan, MD, of Washington University School of Medicine in St. Louis, about 75 percent of the tumors studied have mutations that can be targeted with existing drugs.
School of Medicine scientists, including Richard Wilson, PhD, have completed the largest analysis to date of the genetic mutations underlying ovarian cancer.